The healthcare sector around the world is compelled to address a host of challenges, ranging from the onset of a pandemic to the discovery of new drugs and treatments for different diseases and medical conditions. One of the major areas within the healthcare sphere that continues to attract immense attention is that of the rare neurodegenerative disease treatment and the growing prevalence of several rare diseases worldwide. In addition, the prevalence of the rare neurodegenerative diseases has witnessed a gradual growth over the past couple of decades, owing to surge in the aging population, fast-paced urban lifestyle, etc.
Get Sample PDF Copy: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=78468
Research and development activities have played an imperative role in enabling the growth of the biomedical research space and informatics due to which, understanding the epigenetic modifications, nutrition, and microbiome impact on health has improved considerably.
Rise in prevalence and increase in demand for newer drugs for the treatment of rare neurological disorders have led to the rise in research & development efforts followed by the introduction of innovative neurological disorder drugs. For instance, GlaxoSmithKline plc, Novartis AG, and Merck & Co. have comprehensive R&D programs, wherein these companies focus on the development of new therapeutics for the treatment of neurodegenerative diseases.
Key players in the global rare neurodegenerative disease treatment market include: Allergan plc, Bayer AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Johnson & Johnson